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Despite considerable progress in the past few
years, the rates of morbidity and mortality due to
invasive fungal infections are still unacceptably
high. There is a need for antifungal drugs with
new mechanisms of action that have a broad
spectrum of activity (including resistant patho-
gens) and can be administered both intravenously
and orally. Moreover, agents with these charac-
teristics plus a favourable safety profile and few
drug interactions would be attractive to evaluate
as components of combination therapy regimens
for infections that are difficult to treat.
Predicting the clinical outcome of a systemic
mycosis is often a difficult task, especially when
microbiological resistance is one of the factors
contributing to therapeutic failure. Some of these
factors are host-related, e.g. immune state, site
and severity of infection, and poor compliance
with therapy, while others are associated with the
drug’s characteristics, e.g. dosage, type of com-
pound (fungistatic ⁄ fungicidal), pharmacokinetic
properties, and drug–drug interactions.
AMBISOME COMES OF AGE
Coming of age is the transition from adolescence
to adulthood. The age at which this transition
takes place varies, as does the nature of the
transition. While amphotericin B deoxycholate
has been considered by many to be the reference
standard for the treatment of numerous invasive
fungal infections for over 45 years, toxicities
associated with its use often necessitate treatment
modifications or discontinuation. Lipid-based for-
mulations, including liposomal amphotericin B,
were developed to decrease many of these toxic-
ities. These agents have proven their value in a
variety of clinical settings. The concept of liposo-
mal amphotericin B was formulated in the mid-
1980s, and the first treatment in the Nordic region
took place in 1989. So far, over 500 000 patients
have been treated with AmBisome. The use of
liposomal amphotericin B continues to accelerate.
Recent treatment guidelines include its use as
primary therapy in certain defined situations
where voriconazole is not appropriate [1]. The
evidence would support the use of liposomal
amphotericin B in a wide variety of clinical set-
tings, and recent data support the ability to escalate
the dose in treatment of very serious infections.
Because few comparative studies have been
performed, open-label studies represent a major
source of data on the efficacy of liposomal ampho-
tericin B in proven invasive fungal infections. In
addition, case reports have contributed to our
knowledge regarding this antifungal agent—these
are situations where all the real-life problems of
diagnosis and optimal treatment are presented.
NEW MONOTHERAPY STRATEGIES
The broad spectrum and fungicidal mode of
action of liposomal amphotericin B have
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prompted new strategies to improve antifungal
treatment beyond our current understanding and
experience of empirical and pre-emptive treat-
ment. One approach has been to assess higher
dosing of liposomal amphotericin B. Indeed, the
pharmacodynamic properties, preclinical data
from animal models and the response rates of
patients who received doses >3 mg ⁄ kg ⁄day sug-
gested that liposomal amphotericin B could
improve outcomes and survival. However, a
randomised comparative trial (AmBiLoad trial)
did not demonstrate a greater benefit of a
10 mg ⁄ kg ⁄day dose over the lower does [2].
What is not clear is whether higher doses of
liposomal amphotericin B would benefit truly
high-risk patients, e.g., those with disseminated
disease or zygomycosis. In the setting of invasive
aspergillosis, it is clear that new strategies are
needed. Recent experiences indicate that the
candins used as monotherapy are not optimal
and do not offer any additional benefit over
other broad-spectrum agents for preventing
breakthrough invasive aspergillosis for either
prophylaxis or empirical usage [3–5], or as a
recent European Organisation for Research and
Treatment of Cancer (EORTC) study indicates, as
first-line treatment for invasive aspergillosis [6].
These studies emphasise further the importance
of a fungicidal agent for this disease. Moreover,
new experience should be obtained with candins
at higher dosages, or in combination with lipo-
somal amphotericin B or extended-spectrum
azoles.
COMBINATION STRATEGIES
The benefits of drug combinations have been
demonstrated largely in infectious diseases such
as human immunodeficiency virus infection and
tuberculosis. Generally, the principle of combi-
nation therapy is to combine drugs with differ-
ing pharmacological targets. It has been
predicted that the simultaneous inhibition of
fungal cell-wall biosynthesis and disruption of
cell-wall integrity may result in synergistic inter-
actions against pathogenic yeasts and filamen-
tous fungi.
During the past decade, new antifungals have
been developed that give the clinician an oppor-
tunity to choose from a broader arsenal of drugs
for the treatment of invasive fungal infections.
Moreover, there is now a greater possibility of
combining agents with different modes of action
to achieve an additive or synergistic action for the
most severely ill patients. Clinical studies are
difficult to interpret with this group of patients,
since many of the small number of trials have
been salvage studies, which invariably include
many terminally ill patients, and there are
insufficient and somewhat conflicting data from
in-vitro studies, animal models and clinical
reports on the relative efficacies of different
antifungal combinations. Clearly, before combin-
ing agents, it is important to understand the mode
of action of individual compounds. The optimal
combination would possibly involve drugs with
different pharmacokinetics and sites of action.
Clinical studies are difficult to interpret with
this group of patients, since many of the small
number of trials have been salvage studies, which
invariably include many terminally ill patients,
and there are insufficient and somewhat conflict-
ing data from in vitro studies, animal models and
clinical reports on the relative efficiencies of
different antifungal combinations. Clearly, before
combining agents, it is important to understand
the model of action of individual compounds.
The optimal combination would possibly involve
drugs with different pharmacokinetics and sites
of action. Furthermore, it is important to at least
rule out antagonistic effects that could be delete-
rious to patients.
Although using combinations of agents with
different mechanisms of action is appealing, the
available data are difficult to interpret. Unan-
swered questions include which combination
would be optimal, what endpoint is appropriate,
how much benefit would have to be seen to justify
the adoption of combination therapy, and which
populations are likely to benefit. Despite the
frequent clinical use of antifungal combination
therapy for primary or salvage therapy of inva-
sive fungal infection in many centres, to date, no
randomised study comparing monotherapy
with combination therapy has been performed.
Single-drug therapy, either as first-line or salvage
treatment, rarely gives response rates >50% to
60%. Combination therapy is an attractive con-
cept for treating invasive mycoses. Optimal com-
bination regimens remain unclear. However,
given its broad spectrum, encompassing diffi-
cult-to-treat patients, it is believed that liposomal
amphotericin B is a good drug for invasive
mycosis combination therapy.
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A LOOK INTO THE FUTURE
Recent studies in experimental models of invasive
aspergillosis have suggested that the associa-
tion between amphotericin B and caspofungin
decreases tissue infection and increases survival
[7,8]. Case reports and retrospective studies have
indicated that the combination of caspofungin
with a lipid formulation of amphotericin B or an
azole may be beneficial as salvage therapy. More
clinical studies are obviously needed, but the
following study (the Combistrat trial) may serve
as a model for future trials [9]. Patients with
proven or probable invasive aspergillosis were
randomised in a prospective, open pilot study to
receive either a combination of liposomal ampho-
tericin B at 3 mg ⁄ kg daily and caspofungin 70 mg
on day 1 followed by 50 mg daily thereafter, or
monotherapy with high-dose liposomal ampho-
tericin B (10 mg ⁄ kg ⁄day). Thirty patients (21
men and nine women) with haematological
malignancies were analysed, and there were 15
patients in each arm. The median duration of
treatment was 18 days for the combination group
and 17 days for the high-dose monotherapy
group. At the end of treatment, there were
significantly more favourable overall responses
(partial or complete responses; p 0.028) in the
combination group (ten of 15 patients; 67%) than
in the high-dose monotherapy group (four of 15
patients; 27%). Survival rates at 12 weeks after
inclusion were 100% and 80%, respectively.
Infusion-related reactions occurred in three pa-
tients in the high-dose monotherapy group. A
two-fold increase in serum creatinine occurred in
four of 17 patients (23%) who received high-dose
monotherapy and one of 15 patients (7%) who
received combination therapy; hypokalaemia
<3 mmol ⁄L occurred in three patients and two
patients, respectively.
In addressing future trends in treatment of
systemic fungal infections, it is tempting to
include molecular-genetic-based diagnostics and
therapeutics, and the beginning of a third age of
antifungal agents. However, it is important to
remind ourselves that the foundation of major
advances in our understanding of systemic fun-
gal infections has been, and will remain, careful
clinical observation and the use of appropriate
diagnostic tests. Most modern trends in diagnosis
have resulted from strategies based on key
clinical observations from the past. Disappoint-
ingly, considering that the initial reports on
fungal antigen detection were published 35 years
ago, the evolution of reliable tests for the defin-
itive diagnosis of invasive fungal infections has
been very slow. Further development of surro-
gate markers of invasive aspergillosis and sys-
temic candidosis is urgently required. This
requires considerable investment of resources.
Currently, non-culture-based approaches to diag-
nosis have limited usefulness, with validation
still being needed, although the promise of
improved diagnosis of invasive aspergillosis by
galactomannan detection, PCR and high-resolu-
tion computed tomography is noted.
CONCLUSION
This supplement of Clinical Microbiology and Infec-
tion, focusing primarily on yeast and mould
infections in profoundly immunocompromised
patients, reinforces the value of liposomal ampho-
tericin B as monotherapy, or in combination with
an echinocandin. The success of these strategies
increasingly depends on early diagnosis. Several
infection themes and diagnostic approaches are
presented from all corners of the globe, indicating
the diverse epidemiology of invasive fungal
disease in different climatic areas and in diverse
patient groups. The use of liposomal amphoteri-
cin B has been established in a wide variety of
clinical settings, it has the broadest spectrum of
activity of all currently used antifungals, and
furthermore, resistance has only rarely been
demonstrated. There is an extensive body of
knowledge and history of use (familiarity with)
regarding liposomal amphotericin B which has
been published in the scientific and clinical
literature since 1990. The number of publications
implies a significant and successful level of use.
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